1-20 of 30,845 results for subject:Vaccination
Librarians' tools
- Search time
- 0.306 seconds
- Solr query time
- 0.033 seconds
- Search query
- subject:Vaccination
- We searched for
- subject_t:Vaccination OR subject_t:Immunisation OR subject_t:Vaccines OR subject_ses:93404
Type
House
Session
More
Year
More
Department
More
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
More
Subject
More
Publisher
To ask the Secretary of State for Health and Social Care, what assessment she has made of recent trends in the level of uptake among target groups of covid-19 booster vaccinations; and what steps her Department is taking to (a) promote public awareness and (b) increase the take-up of the...
To ask the Secretary of State for Health and Social Care, what assessment she has made of recent trends in the level of uptake among target groups of covid-19 booster vaccinations; and what steps her Department is taking to (a) promote public awareness and (b) increase the take-up of the...
To ask the Secretary of State for Health and Social Care, what data her Department holds on the number of COVID vaccines issued, unused and discarded; and what steps she is taking to adjust supply to local centres to meet demand.
To ask the Secretary of State for Health and Social Care, what data her Department holds on the number of COVID vaccines issued, unused and discarded; and what steps she is taking to adjust supply to local centres to meet demand.
To ask the Secretary of State for Health and Social Care, is she will take steps to allow GPs to administer surplus COVID vaccinations to key workers, medical staff and vulnerable patients.
To ask the Secretary of State for Health and Social Care, is she will take steps to allow GPs to administer surplus COVID vaccinations to key workers, medical staff and vulnerable patients.
To ask the Secretary of State for Health and Social Care, what safeguards exist to ensure that faith-based guidance distributed in support of vaccination programmes is clearly distinguishable from official public-health advice.
To ask the Secretary of State for Health and Social Care, what safeguards exist to ensure that faith-based guidance distributed in support of vaccination programmes is clearly distinguishable from official public-health advice.
To ask the Secretary of State for Health and Social Care, what guidance exists for schools on distributing healthcare materials produced by faith-based organisations alongside NHS vaccination information.
To ask the Secretary of State for Health and Social Care, what guidance exists for schools on distributing healthcare materials produced by faith-based organisations alongside NHS vaccination information.
To ask the Secretary of State for Health and Social Care, if her Department will take steps to repeat the Men B vaccinations for 17 and 18 year olds to ensure that children born before the Men B vaccination was added to the Childhood Immunisation Schedule in 2015 have access...
To ask the Secretary of State for Health and Social Care, if her Department will take steps to repeat the Men B vaccinations for 17 and 18 year olds to ensure that children born before the Men B vaccination was added to the Childhood Immunisation Schedule in 2015 have access...
To ask the Secretary of State for Health and Social Care, how many of the suspected adverse reaction reports of unknown age for the COVID-19 Vaccine Moderna monovalent were followed up by the Medicines and Healthcare products Regulatory Agency to try and recover the missing information.
To ask the Secretary of State for Health and Social Care, how many of the suspected adverse reaction reports of unknown age for the COVID-19 Vaccine Moderna monovalent were followed up by the Medicines and Healthcare products Regulatory Agency to try and recover the missing information.
The requested information is not held centrally by the Department and could only be collated and verified at disproportionate cost.
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the potential (a) health benefits and (b) cost savings to the NHS of extending eligibility for the shingles vaccination to immunocompetent people who were aged 65 to 69 before 1 September 2023...
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the potential (a) health benefits and (b) cost savings to the NHS of extending eligibility for the shingles vaccination to immunocompetent people who were aged 65 to 69 before 1 September 2023...
To ask the Secretary of State for Health and Social Care, whether her Department has reviewed the decision not to include immunocompetent people who were aged 65 to 69 before 1 September 2023 in the catch-up arrangements for the shingles vaccination programme; and whether he plans to extend eligibility to...
To ask the Secretary of State for Health and Social Care, whether her Department has reviewed the decision not to include immunocompetent people who were aged 65 to 69 before 1 September 2023 in the catch-up arrangements for the shingles vaccination programme; and whether he plans to extend eligibility to...
To ask the Secretary of State for Health and Social Care, whether she plans to enable GP practices to deliver MenB catch-up vaccination in the future, particularly practices serving populations at increased risk, such as those caring for large numbers of young people or university students.
To ask the Secretary of State for Health and Social Care, whether she plans to enable GP practices to deliver MenB catch-up vaccination in the future, particularly practices serving populations at increased risk, such as those caring for large numbers of young people or university students.
To ask the Secretary of State for Health and Social Care, whether he considered allowing GP practices to participate in the MenB vaccination catch-up programme alongside community pharmacies.
To ask the Secretary of State for Health and Social Care, whether he considered allowing GP practices to participate in the MenB vaccination catch-up programme alongside community pharmacies.
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of the exclusion of people under 75 with severe chronic obstructive pulmonary disease (COPD) from the eligibility criteria for COVID-19 vaccinations; and whether she plans to review those criteria for...
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of the exclusion of people under 75 with severe chronic obstructive pulmonary disease (COPD) from the eligibility criteria for COVID-19 vaccinations; and whether she plans to review those criteria for...
To ask His Majesty's Government, in light of the NHS Oversight Framework including vaccination metrics for only the measles, mumps, rubella and varicella and healthcare worker influenza vaccination programmes, what steps they will take to ensure robust accountability for all national vaccination programmes following the transfer of commissioning responsibilities to...
To ask His Majesty's Government, in light of the NHS Oversight Framework including vaccination metrics for only the measles, mumps, rubella and varicella and healthcare worker influenza vaccination programmes, what steps they will take to ensure robust accountability for all national vaccination programmes following the transfer of commissioning responsibilities to...
We have established a programme that will, alongside closer working and a safe transfer checklist, help to ensure that integrated care boards (ICBs) are ready to take on their new responsibilities for vaccination from April 2027. We will also ensure there is appropriate accountability for vaccination services after the responsibility for their commissioning is delegated to ICBs. Work is ongoing and aligned to the merger of the Department of Health and Social Care and NHS England.
No changes in the current reporting frameworks in this area are planned, but we keep all such matters under regular review.
The Department does not collect data on the costs of responding to outbreaks of vaccine-preventable infectious disease, but the methodology for assessing the cost-effectiveness of vaccination programmes routinely accounts for benefits such as avoided National Health Service and social care costs, as well as improved health outcomes.
To ask His Majesty's Government what consideration they gave to placing a statutory duty on the Secretary of State to lay before Parliament an annual report on the performance of national immunisation programmes, including health inequalities and progress towards national targets, when developing the Health Bill.
To ask His Majesty's Government what consideration they gave to placing a statutory duty on the Secretary of State to lay before Parliament an annual report on the performance of national immunisation programmes, including health inequalities and progress towards national targets, when developing the Health Bill.
We have established a programme that will, alongside closer working and a safe transfer checklist, help to ensure that integrated care boards (ICBs) are ready to take on their new responsibilities for vaccination from April 2027. We will also ensure there is appropriate accountability for vaccination services after the responsibility for their commissioning is delegated to ICBs. Work is ongoing and aligned to the merger of the Department of Health and Social Care and NHS England.
No changes in the current reporting frameworks in this area are planned, but we keep all such matters under regular review.
The Department does not collect data on the costs of responding to outbreaks of vaccine-preventable infectious disease, but the methodology for assessing the cost-effectiveness of vaccination programmes routinely accounts for benefits such as avoided National Health Service and social care costs, as well as improved health outcomes.
To ask His Majesty's Government what assessment they have made of the costs associated with responding to outbreaks of vaccine-preventable diseases in 2025–26; whether they collect data on the costs of vaccine procurement and deployment, and outbreak response by disease; and, if so, whether they intend to publish this information.
To ask His Majesty's Government what assessment they have made of the costs associated with responding to outbreaks of vaccine-preventable diseases in 2025–26; whether they collect data on the costs of vaccine procurement and deployment, and outbreak response by disease; and, if so, whether they intend to publish this information.
We have established a programme that will, alongside closer working and a safe transfer checklist, help to ensure that integrated care boards (ICBs) are ready to take on their new responsibilities for vaccination from April 2027. We will also ensure there is appropriate accountability for vaccination services after the responsibility for their commissioning is delegated to ICBs. Work is ongoing and aligned to the merger of the Department of Health and Social Care and NHS England.
No changes in the current reporting frameworks in this area are planned, but we keep all such matters under regular review.
The Department does not collect data on the costs of responding to outbreaks of vaccine-preventable infectious disease, but the methodology for assessing the cost-effectiveness of vaccination programmes routinely accounts for benefits such as avoided National Health Service and social care costs, as well as improved health outcomes.
To ask the Secretary of State for Environment, Food and Rural Affairs, what steps she is taking to ensure that sufficient supplies of vaccines against bluetongue virus are available to livestock keepers; and what steps she is taking to improve the availability and timely distribution of those vaccines.
To ask the Secretary of State for Environment, Food and Rural Affairs, what steps she is taking to ensure that sufficient supplies of vaccines against bluetongue virus are available to livestock keepers; and what steps she is taking to improve the availability and timely distribution of those vaccines.
Defra and the Veterinary Medicines Directorate (VMD) are working closely with manufacturers, wholesalers and veterinary bodies to monitor availability and support continuity of supply. Defra and VMD have taken proactive regulatory action to expedite the import of authorised Northern Ireland and European Union-authorised BTV-3 vaccines, helping to increase vaccine availability in Great Britain.
To ask the Secretary of State for Environment, Food and Rural Affairs, what her Department's long-term education, vaccination and disease-control strategy is to prevent bluetongue virus serotype 3 becoming an annual cycle of infection, reproductive losses and reduced livestock production.
To ask the Secretary of State for Environment, Food and Rural Affairs, what her Department's long-term education, vaccination and disease-control strategy is to prevent bluetongue virus serotype 3 becoming an annual cycle of infection, reproductive losses and reduced livestock production.
Bluetongue will likely recur in 2027. The best way to protect against reproductive and production losses is to vaccinate early. Defra supports the industry-led Battle Bluetongue campaign and continues to encourage animal keepers to speak to their vet about vaccination. The department take part in industry led webinars and provide other communications. During her recent roundtable with industry representatives affected by bluetongue on 8 September, Baroness Hayman heard first-hand the challenges faced by the sector, the importance of partnership working, and the need to strengthen long-term preparedness and resilience across the sector.
To ask the Secretary of State for Environment, Food and Rural Affairs, if she will consider a coordinated programme combining large-scale vaccination, Culicoides surveillance and systematic genetic monitoring, similar to measures adopted in France, to tackle the spread of bluetongue virus serotype 3.
To ask the Secretary of State for Environment, Food and Rural Affairs, if she will consider a coordinated programme combining large-scale vaccination, Culicoides surveillance and systematic genetic monitoring, similar to measures adopted in France, to tackle the spread of bluetongue virus serotype 3.
This Government keeps its approach to bluetongue under continual review and considers scientific evidence and international experience when developing control policies. While the decision to vaccinate remains one for animal keepers, in consultation with their private vets, we have worked closely with sector representatives to encourage take-up, including supporting the Battle Bluetongue campaign to advocate for vaccination. The Animal and Plant Health Agency publishes a heat map of suspected and confirmed cases. The bluetongue virus genome is not prone to variation and recent genetic sequencing shows the virus in 2026 is very similar to the virus first detected in the Netherlands and later England in 2023.
To ask His Majesty's Government how the modelling being considered by the Joint Committee on Vaccination and Immunisation is informing their assessment of the affordability and cost-effectiveness of expanding shingles vaccination to adults aged 80 years and over; and what timeframe they anticipate for a decision on implementing this advice.
To ask His Majesty's Government how the modelling being considered by the Joint Committee on Vaccination and Immunisation is informing their assessment of the affordability and cost-effectiveness of expanding shingles vaccination to adults aged 80 years and over; and what timeframe they anticipate for a decision on implementing this advice.
The phased roll-out of the shingles vaccination programme down to age 60 is being implemented in line with the advice of the Joint Committee on Vaccination and Immunisation (JCVI) and was agreed as a means of maximising population benefit and cost-effectiveness, whilst taking account of National Health Service delivery capacity. Shingles vaccination uptake is closely monitored at national and commissioning region levels.
With regards to the JCVI's advice to expand the programme to adults aged 80 years and over, I refer the Noble Baroness to the answer provided in the House of Commons on 30 June in response to Question 3226, which, for ease of reference, is reproduced below.
The Government is considering the Joint Committee on Vaccination and Immunisation’s advice on shingles vaccinations, examining factors including clinical benefits, affordability and cost effectiveness.
No decision has yet been taken on any expansion of the existing shingles vaccination programme to include adults aged 80 years old or over.
For any routine vaccination programme which the Government decides to implement, efforts to introduce or expand the programme are determined by factors including availability of supply, contractual arrangement on supply, affordability, workforce capacity and impact on other programmes.
To ask His Majesty's Government what assessment they have made of the potential impact of the phased rollout of shingles vaccination for adults aged 60 years and over on health inequalities, including differences in access and uptake across socioeconomic and geographic groups.
To ask His Majesty's Government what assessment they have made of the potential impact of the phased rollout of shingles vaccination for adults aged 60 years and over on health inequalities, including differences in access and uptake across socioeconomic and geographic groups.
The phased roll-out of the shingles vaccination programme down to age 60 is being implemented in line with the advice of the Joint Committee on Vaccination and Immunisation (JCVI) and was agreed as a means of maximising population benefit and cost-effectiveness, whilst taking account of National Health Service delivery capacity. Shingles vaccination uptake is closely monitored at national and commissioning region levels.
With regards to the JCVI's advice to expand the programme to adults aged 80 years and over, I refer the Noble Baroness to the answer provided in the House of Commons on 30 June in response to Question 3226, which, for ease of reference, is reproduced below.
The Government is considering the Joint Committee on Vaccination and Immunisation’s advice on shingles vaccinations, examining factors including clinical benefits, affordability and cost effectiveness.
No decision has yet been taken on any expansion of the existing shingles vaccination programme to include adults aged 80 years old or over.
For any routine vaccination programme which the Government decides to implement, efforts to introduce or expand the programme are determined by factors including availability of supply, contractual arrangement on supply, affordability, workforce capacity and impact on other programmes.